Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in art-naïve ACTG clinical trials participants

Pacific Symposium on Biocomputing 2011, PSB 2011

Volumn , Issue , 2011, Pages 253-264

  Grady, Benjamin J ^a   Torstenson, Eric S ^a   McLaren, Paul J ^b   De Bakker, Paul I W ^b   Haas, David W ^c   Robbins, Gregory K ^d   Gulick, Roy M ^e   Haubrich, Richard ^f   Ribaudo, Heather ^b   Ritchie, Marylyn D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AIDS CLINICAL TRIAL; ANTIRETROVIRALS; CLASS I; CLINICAL TRIAL; DATA SETS; EFAVIRENZ; ETHNIC GROUPS; GENE-GENE INTERACTION; GENETIC ARCHITECTURE; GENETIC CODE; GENETIC EFFECTS; GENETIC VARIATION; HISPANICS; INTERACTION MODEL; INTRACELLULAR TRANSPORT; LOGISTIC REGRESSION MODELS; MULTIDRUG RESISTANCE; MULTIPLE COMPARISON; PERSONALIZED MEDICINES; PHARMACOGENOMICS; PROTEIN INTERACTION NETWORKS; RANDOMIZED CLINICAL TRIALS;

BIOFILTERS; DRUG INTERACTIONS; EXPERIMENTS; HEALTH CARE; LOGISTICS; PROTEINS; REGRESSION ANALYSIS; SOFTWARE PACKAGES;

GENES;

ABC TRANSPORTER; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DRUG RECEPTOR; EFAVIRENZ; INWARDLY RECTIFYING POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR; TAP1 PROTEIN, HUMAN;

ANTIVIRAL RESISTANCE; ARTICLE; BIOLOGY; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPISTASIS; GENETIC ASSOCIATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE;

ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOXAZINES; COMPUTATIONAL BIOLOGY; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; EPISTASIS, GENETIC; GENOME-WIDE ASSOCIATION STUDY; HIV INFECTIONS; HIV-1; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; RISK FACTORS; SOFTWARE; TREATMENT FAILURE;

EID: 84859233860     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (31)

1. UNAIDS. 2008 Report on the Global AIDS epidemic. 129-158. 2008.
2. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R et al. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 2010; 5:298-304.
3. Tsibris AM, Hirsch MS. Antiretroviral therapy in the clinic. J Virol 2010; 84:5458-5464.
4. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
5. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P et al. Twodose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288:189-198.
6. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
7. Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res 2010; 85:201-209.
8. d'Ettorre G, Zaffiri L, Ceccarelli G, Mastroianni CM, Vullo V. The role of HIV-DNA testing in clinical practice. New Microbiol 2010; 33:1-11.
9. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5:262-270.
10. Oldenburg J, Bevans CG, Muller CR, Watzka M. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 2006; 8:347-353.
11. Glaxo Smith Kline. Ziagen Medication Guide. 2009.
12. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
13. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol 2010; 28:237-245.
14. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63:S3-S8.
15. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
16. Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. Nat Rev Drug Discov 2005; 4:911-918.
17. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet 2002; 11:2463-2468.
18. Culverhouse R, Klein T, Shannon W. Detecting epistatic interactions contributing to quantitative traits. Genet Epidemiol 2004; 27:141-152.
19. Moore JH, Williams SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. Bioessays 2005; 27:637-646.
20. Bateson,W, Saunders,ER, Punnett,RC, Hurst,CC. Reports to the Evolution Committee of the Royal Society, Report II. London: Harrison and Sons; 1905.
21. Fisher RA. The correlations between relatives on the supposition of Mendelian inheritance. Trans R Soc Edinb 1918; 52:399-433.
22. Bush WS, Dudek SM, Ritchie MD. Biofilter: a knowledge-integration system for the multilocus analysis of genome-wide association studies. Pac Symp Biocomput 2009;368-379.
23. Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF et al. A multiinvestigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 2003; 4:287-300.
24. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
25. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, III et al. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769-781.
26. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, III et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
27. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitorsparing regimens for initial HIV treatment. AIDS 2009; 23:1109-1118.
28. Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP et al. A randomized study of antiviral medication switch at lower-versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 2007; 12:531-541.
29. Robbins GK, De G, V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
30. Shafer RW, Smeaton LM, Robbins GK, De G, V, Snyder SW, D'Aquila RT et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304-2315.
31. Grady BJ, Torstenson ES, Dudek SM, Giles P, Ritchie MD. Finding Unique Filter Sets in PLATO: A Precursor to Efficient Interaction Analysis in GWAS Data. Proceedings of the Pacific Symposium in Biocomputing 2009.